

CEREBROVASCULAR CONTRIBUTIONS TO COGNITIVE IMPAIRMENT & DEMENTIA

David S. Knopman MD FAAN

Mayo Clinic
Rochester MN

Disclosures: Dr. Knopman serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by Biogen, TauRX Pharmaceuticals, Lilly Pharmaceuticals; and receives research support from the NIH.

Summary: Stroke and cerebrovascular (CVD) imaging lesions are common in the elderly and increase with advancing age. However, only a minority of elderly have stroke or visible CVD imaging lesions. In those individuals, CVD is often a contributor, but rarely a sole cause, of cognitive impairment. CVD acts in an additive manner with other pathologies, particularly those of Alzheimer disease (AD). The clinical diagnosis of a vascular contribution to cognitive impairment and its presumed relevance can be inferred from: (a) history of stroke especially when the onset of cognitive impairment is temporally related to the stroke; (b) a history of cardiovascular disease (coronary artery disease, congestive heart failure, atrial fibrillation, myocardial infarct); (c) presence of vascular risk factors (especially diabetes, hypertension, cigarette smoking); and (d) imaging evidence of white matter hyperintensities (WMH) or infarcts. However, all of these features are indirect measures of the true impact of CVD on cognition: the CVD lesion that is most proximate to cognitive decline is not certain. Microinfarcts, disconnection via WM disruption or cortical thinning are candidate mechanisms. The physics of MR make it unlikely that we will be able to image microinfarcts in life, but improved imaging techniques such as diffusion tensor imaging may add to our ability to diagnosis white matter dysfunction. Reduction of the vascular contribution to cognition is feasible now, through management or avoidance in midlife of vascular risk factors.

Understanding the cerebrovascular contribution to later life cognitive has undergone a transformation in the past decade. Rather than conceptualizing an entity of “vascular dementia” as present or absent, the emerging concept of the vascular contribution to cognitive impairment (VCCI) envisions a collaborative, supportive and additive role for cerebrovascular disease in late life cognitive impairment in conjunction with other diseases, especially Alzheimer’s disease (AD).

Some vascular pathology exists in 29% to 41% of dementia cases coming to autopsy in population-based cohorts, but though only 9% to 10% have only vascular pathology to account for their dementia¹⁻⁴. Cerebrovascular disease usually occurs in the setting of concomitant neurodegenerative diseases especially Alzheimer’s disease⁴⁻⁷. Antemortem studies are now able to recognize biomarkers for both AD and cerebrovascular disease. For example, a study of cognitively impaired patients with multiple infarcts on MR imaging showed that about a third also had abnormal amyloid imaging using amyloid PET⁸. When AD and CVD occur together their effect is additive not multiplicative on cognition⁹.

The conceptual change has an empiric basis. The NINDS-AIREN diagnostic criteria¹⁰ based on the “big, known stroke” model have had poor predictive value^{1,3,11-13}. Specifically, while a history of a stroke is undoubtedly a risk factor for future cognitive decline¹⁴⁻¹⁹, a history of overt stroke is uncommon in persons with a high burden of cerebrovascular disease²⁰. Second, the notion that there is a distinct cognitive profile of “vascular dementia” is a naive over-simplification. While it is the case that cognitive slowing and abulia are characteristic of vascular dementia and memory impairment is less evident²¹, those features are neither specific nor sensitive²². The notion of “abrupt onset” as a diagnostic feature of cerebrovascular etiology of cognitive impairment is of limited value, as are so-called “focal neurological signs.” Both are too nonspecific. While a history of cognitive impairment that closely follows an overt stroke is a reliable marker of relevant CVD, persons with that profile constitute on a

small fraction of VCCI. Most VCCI has no distinctive temporal profile: it can exhibit plateaus as well as steady decline.

Imaging evidence of cerebrovascular disease captures much more covert pathology than is evident from clinical history alone. Good quality MR imaging is essential for diagnosing cerebrovascular pathology. However, imaging evidence of white matter hyperintensities, small (lacunar) or larger infarcts or cortical microbleeds are better thought of on a continuum of risk rather than as categorical indicators of certain relevance for cognitive impairment. Both lacunar infarcts²³⁻²⁶ and white matter hyperintensities²⁷⁻³¹ are more common in persons with cognitive impairment than in cognitively normal elderly, but a large fraction of the latter may have such lesions.

Table 1 summarizes the major clinical and imaging features that support a diagnosis of a vascular contribution to cognitive impairment. Table 1 represents the author's own scheme, not one that has any been adopted by any consensus group.

The critical lesion causing cognitive impairment in cerebrovascular disease remains elusive, and in fact, might be more than one entity. Large vessel extracranial disease of the carotid or vertebrobasilar systems are not the proximal cause of cognitive impairment. White matter hyperintensities are neither specific nor sensitive enough to represent the critical lesion for cerebrovascular cognitive impairment. Nor is a single lacunar infarct. Instead, both white matter hyperintensities and lacunar infarcts might be best thought of as proxies for some underlying critical pathology. Extensive white matter ischemic disease could lead to cortical disconnection and thus induce cognitive impairment,^{32,33} but diffusion tensor imaging rather than T2 weighted scans may better detect the critical pathology. Microinfarcts are a strong candidate for being a core lesion of VCI.³⁴ Imaging evidence of cerebrovascular disease can be used to infer microvascular pathology, but MR imaging at present cannot diagnose microinfarcts because most microinfarcts are smaller than the resolution of 3T MRI, ie <1 mm in diameter

Table 1. An Index of Cerebrovascular Disease in Cognitive Impairment (from ³⁵)

Not supportive - Low Probability of CVD	Supportive- Moderate Probability of CVD	Most strongly supportive- High Probability of CVD
No history of stroke	Any stroke above midbrain by history, without subsequent impact on cognition	Stroke temporally related to onset of dementia or worsening of cognition
One focal sign (eg an unexplained extensor toe sign or a reflex asymmetry)	2 or 3 neurologic signs suggestive of cerebrovascular origin	Multiple neurologic signs strongly suggestive of cerebrovascular origin
White matter Hyperintensities -None or minimal	White matter Hyperintensities - Mild to moderate	White matter Hyperintensities -Severe
None or one lacune	2 to 3 Lacunes	4 or more Lacunes
No cortical infarcts or only one small cortical infarct	Cortical infarct, single	Cortical infarcts, large, multiple
No infarcts in critical regions	Lacune or small infarct only in critical regions	Hippocampal, caudate, thalamic infarct larger than lacune

References

1. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. *Br J Psychiatry* 1999;174:45-50.
2. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. *J Am Geriatr Soc* 1999;47:564-9.

3. Knopman D, Parisi JE, Boeve BF, et al. Vascular Dementia in a Population-based autopsy study. *Arch Neurol* 2003;60:569-76.
4. White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. *J Alzheimers Dis* 2009;18:713-25.
5. Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. *Arch Neurol* 2011;68:1049-56.
6. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology* 2007;69:2197-204.
7. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. *Ann Neurol* 2008;64:168-76.
8. Lee JH, Kim SH, Kim GH, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. *Neurology* 2011;77:18-25.
9. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. *Brain* 2015;138:761-71.
10. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology* 1993;43:250-60.
11. Gold G, Bouras C, Canuto A, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. *Am J Psychiatry* 2002;159:82-7.
12. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). *Stroke* 1996;27:30-6.
13. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. *Stroke* 2000;31:2952-7.
14. Knopman DS, Roberts RO, Geda YE, et al. Association of prior stroke with cognitive function and cognitive impairment: A population-based study. *Arch Neurol* 2009;66:614-19.
15. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Poststroke dementia: incidence and relationship to prestroke cognitive decline. *Neurology* 2001;57:1216-22.
16. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). *Neurology* 1996;46:154-9.
17. Pohjasvaara T, Mantyla R, Salonen O, et al. MRI correlates of dementia after first clinical ischemic stroke. *J Neurol Sci* 2000;181:111-7.
18. Gamaldo A, Moghekar A, Kilada S, Resnick SM, Zonderman AB, O'Brien R. Effect of a clinical stroke on the risk of dementia in a prospective cohort. *Neurology* 2006;67:1363-9.
19. Allan LM, Rowan EN, Firbank MJ, et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. *Brain* 2011;134:3713-24.
20. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. *Ann Neurol* 2007;62:59-66.
21. Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. *Neurology* 1999;53:670-8.
22. Reed BR, Mungas DM, Kramer JH, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. *Brain* 2007;130:731-9.
23. Longstreth WT, Jr., Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. *Arch Neurol* 1998;55:1217-25.
24. Brott T, Tomsick T, Feinberg W, et al. Baseline silent cerebral infarction in the Asymptomatic Carotid Atherosclerosis Study. *Stroke* 1994;25:1122-9.
25. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. *Stroke* 2003;34:392-6.

26. Bryan RN, Cai J, Burke G, et al. Prevalence and anatomic characteristics of infarct-like lesions on MR images of middle-aged adults: the atherosclerosis risk in communities study. *AJNR Am J Neuroradiol* 1999;20:1273-80.
27. Liao D, Cooper L, Cai J, et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. *Neuroepidemiology* 1997;16:149-62.
28. Breteler MM, van Amerongen NM, van Swieten JC, et al. Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. *Stroke* 1994;25:1109-15.
29. van Swieten JC, Geyskes GG, Derix MM, et al. Hypertension in the elderly is associated with white matter lesions and cognitive decline. *Ann Neurol* 1991;30:825-30.
30. Longstreth WT, Jr., Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. *Stroke* 1996;27:1274-82.
31. Breteler MM, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. *Neurology* 1994;44:1246-52.
32. Lawrence AJ, Chung AW, Morris RG, Markus HS, Barrick TR. Structural network efficiency is associated with cognitive impairment in small-vessel disease. *Neurology* 2014;83:304-11.
33. Tuladhar AM, Reid AT, Shumskaya E, et al. Relationship between white matter hyperintensities, cortical thickness, and cognition. *Stroke* 2015;46:425-32.
34. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. *Lancet Neurol* 2012;11:272-82.
35. Knopman DS. Dementia and cerebrovascular disease. *Mayo Clin Proc* 2006;81:223-30.